Menveo

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0123	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	28/11/2024	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

X/0119	Annex I_2.(d) Change or addition of a new pharmaceutical form	19/09/2024	25/11/2024	SmPC, Labelling and PL	
IB/0121/G	This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	16/07/2024	n/a		
IA/0120	A.7 - Administrative change - Deletion of manufacturing sites	21/08/2023	n/a		
IB/0118	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	21/06/2023	22/05/2024	SmPC and Labelling	
IB/0116/G	This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	05/06/2023	n/a		
IB/0117	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting	02/05/2023	n/a		

	material/intermediate/reagent - Other variation				
II/0115/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	02/03/2023	n/a		
WS/2325	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	17/11/2022	n/a		
II/0112	Submission of an updated RMP to remove several safety concerns. RMP version 10 has been approved with this procedure. C.I.11.b - Introduction of, or change(s) to, the	27/10/2022	n/a		

	obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
IB/0113	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	19/08/2022	n/a		
II/0106/G	This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	22/04/2022	n/a		
IA/0111	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	05/04/2022	n/a		
IB/0110	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished	23/03/2022	n/a		

	product - Other variation				
IA/0109/G	This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	31/01/2022	n/a		
IB/0108	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/01/2022		SmPC	
IB/0105/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	10/01/2022	n/a		
II/0103	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	11/11/2021	n/a		

IA/0107	B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits	03/11/2021	n/a		
IB/0104	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	14/10/2021		SmPC, Labelling and PL	Update of the annexes to add a new pack size (EU/1/10/614/004).
II/0101	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	08/07/2021	n/a		
IB/0102	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	07/07/2021	n/a		
IB/0100	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	12/04/2021	n/a		
IB/0099	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	05/03/2021	n/a		
IB/0098/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters	27/01/2021	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
IB/0097	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	15/01/2021	n/a		
PSUSA/1969/ 202003	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to Corynebacterium diphtheriae CRM197 protein)	29/10/2020	n/a		PRAC Recommendation - maintenance
IB/0096/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	27/10/2020	n/a		

II/0094/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	16/07/2020	n/a		
II/0093	Update of section 4.8 of the SmPC in order to include lymphadenopathy as a new expected adverse reaction after vaccination in Post-marketing experience based on final results from study V59_77 and substantiated by supportive clinical data (mainly to establish frequency), following CHMP assessment of procedure P46/039. Section 4 of the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	23/01/2020	29/01/2021	SmPC, Annex II, Labelling and PL	
IB/0092	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement	07/01/2020	n/a		

	or addition) for the AS or a starting material/intermediate				
IB/0091	B.II.d.2.z - Change in test procedure for the finished product - Other variation	25/11/2019	n/a		
IB/0090	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	14/10/2019	n/a		
IB/0089	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	23/08/2019	n/a		
WS/1621	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	18/07/2019	n/a		
IB/0088/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of	09/07/2019	n/a		

	the finished or intermediate product - Minor change in the manufacturing process				
II/0083	Update of section 4.5 of the SmPC in order to include reference to concomitant administration with Meningococcal group B vaccine, based on results from study V72_56, previously submitted and assessed as part of procedure P46/035 for Menveo. The Package Leaflet (Section 2) is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	29/05/2019	23/01/2020	SmPC and PL	Data from a phase III open label randomised trial assessing the impact of concomitant administration of MenACWY with rMenB vs the administration of either vaccine alone in healthy infants showed that the immune response following administration of MenACWY vaccine was higher or similar in the rMenB+ACWY group compared with that in the MenACWY group. Also from a safety perspective, rMenB can be given concomitantly with MenACWY. The product information is updated accordingly.
II/0078/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	21/03/2019	23/01/2020	SmPC	

	B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information				
IA/0086	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	20/03/2019	n/a		
WS/1532	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation	14/03/2019	n/a		
IB/0085	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	25/02/2019	n/a		
IB/0084/G	This was an application for a group of variations. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting	20/02/2019	n/a		

	material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
WS/1504	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Section 4.4 of the SmPC for four GSK meningococcal vaccines to include a safety warning of the risk for invasive disease caused by Neisseria meningitidis relative to individuals with familial complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example eculizumab). The Package Leaflets (PL) are updated accordingly. In addition, the Worksharing Applicant (WSA) took the opportunity to amend the list of local representatives in the PL of Bexsero and Menveo. Minor editorial updates in the SmPC of Bexsero and Menveo were also carried out. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	24/01/2019	23/01/2020	SmPC and PL	Based on the review of the literature reports well as the cases from the MAH's safety database, the Bexsero /Menveo SmPC has been updated to reflect that persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis (of the group relevant for each vaccine), even if they develop antibodies following vaccination with Bexsero (/Menveo, as applicable). The PLs have been updated accordingly.
IB/0081/G	This was an application for a group of variations.	08/01/2019	n/a		

	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IB/0077/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits	04/01/2019	n/a		
IB/0080	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	10/12/2018	n/a		
IB/0076/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	21/08/2018	n/a		

	of the AS				
IA/0075	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	20/07/2018	n/a		
IB/0074	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	05/04/2018	n/a		
N/0073	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/03/2018	23/01/2020	Labelling	
IB/0071	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	05/03/2018	n/a		
IB/0072	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	01/03/2018	n/a		
IB/0070	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	31/10/2017	n/a		
PSUSA/1969/ 201703	Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to Corynebacterium diphtheriae CRM197 protein)	26/10/2017	n/a		PRAC Recommendation - maintenance
IA/0069/G	This was an application for a group of variations.	03/08/2017	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State				
IB/0068/G	This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	27/07/2017	n/a		
II/0065	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	22/06/2017	n/a		

IB/0066	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	22/05/2017	n/a		
IA/0064/G	This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.	16/01/2017	n/a		
N/0063	Update of the package leaflet with revised contact details of the local representatives for Italy and the United Kingdom. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	30/08/2016	23/01/2020	PL	
II/0062	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	23/06/2016	n/a		
II/0056	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/05/2016	n/a		
IB/0060/G	This was an application for a group of variations.	12/02/2016	n/a		

	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation				
IB/0059/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product	16/12/2015	n/a		
IG/0639	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	09/12/2015	n/a		
IB/0058	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/11/2015	n/a		
IB/0055/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	06/11/2015	n/a		

	of the AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation				
IAIN/0057/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	30/09/2015	02/03/2016	SmPC, Annex II, Labelling and PL	
IB/0054/G	This was an application for a group of variations.	19/08/2015	n/a		

	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0053	To extend the shelf life of MenA Lyophilised component of Menveo from 2 to 3 years. In addition, the MAH took the opportunity to remove the Stein manufacturing site from Module 3 which has never been used to produce Men A Lyophilised component for the EU market. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	03/08/2015	02/03/2016	SmPC	
II/0052	Update of section 5.1 of the SmPC to include the immunogenicity data after 2 doses versus 1 dose vaccination in children 2 through 10 years of age based on the final CSR of the study V59_57 (ANX 022). The Annex II has been amended accordingly. C.I.11.b - Introduction of, or change(s) to, the	23/07/2015	02/03/2016	SmPC and Annex II	In a randomized, observer-blind study (V59_57) conducted in US, immunogenicity of a 2-dose series and a single dose of Menveo was compared in children 2 through 5 and 6 through 10 years of age (N=715). At baseline, the percentage of subjects with hSBA ≥1:8 across the two age strata was 1%-5% for serogroup A, 13%-28% for serogroup C, 42%-64% for serogroup W135,

	obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				and 6%-19% for serogroup Y. At 1 month post last vaccination, the percentages of subjects with hSBA ≥1:8 in the 2-dose group and in the single dose group across the two age strata were: 90%-95% vs 76%–80% for serogroup A, 98%-99% vs 76%-87% for serogroup C, 99% vs 93%-96% for serogroup W135, and 96% vs 65%-69% for serogroup Y. GMTs were higher in the 2-dose group than the single dose group at 1 month after vaccination in both age strata; however, this difference was less pronounced in the older age stratum. At 1 year post last vaccination, the percentages of subjects with hSBA ≥1:8 after the 2-dose series and the single dose were both lower than at 1 month post-vaccination (30% after the 2-dose series, 11%-20% after the single dose for serogroup A; 61%-81% and 41%-55% for serogroup C; 92%-94% and 90%-91% for serogroup W135; 67%-75% and 57%-65% for serogroup Y). The differences between hSBA GMTs in the 2-dose and the single dose groups at 1 year after vaccination were lower than those seen at 1 month post-vaccination. The clinical benefit of a 2-dose vaccination series in children 2 through 10 years of age is not known.
II/0051/G	This was an application for a group of variations. Update of sections 4.8 "Undesirable effects" in order to include the safety data from studies in children aged ≥2 years and section 4.4 "Special warnings and precautions for use" to harmonize class labelling. The Package has been updated accordingly. The requested group of variations proposed amendments to the Summary of Product	26/03/2015	02/03/2016	SmPC and PL	

	Characteristics and Package Leaflet. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
II/0050	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	26/02/2015	n/a		
II/0049	Update of section 5.1 of the SmPC to include the additional 5 year persistence data as consequence of submitted final CSR of study V59P20E1 in fulfillment of MEA 025. The MAH also took the opportunity to include within section 5.1 of the SmPC correction derived from V59P13E1-Erratum and to correct a minor typo. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	26/02/2015	02/03/2016	SmPC	Antibody persistence at 5 years after primary vaccination was assessed in study V59P20E1, this was an extension of study V59P20. There was antibody persistence observed against serogroups C, W135 and Y, with the percentages of subjects with hSBA ≥ 1:8 being 32% and 56% against serogroup C in subjects 2-5 and 6-10 years of age, respectively, 74% and 80% against serogroup W135, and 48% and 53% against serogroup Y. GMTs were respectively 6.5 and 12 for serogroup C, 19 and 26 for serogroup W135, and 8.13 and 10 for serogroup Y. For serogroup A, 14% and 22% of subjects 2-5 and 6-10 years of age, respectively, had hSBA ≥ 1:8 (GMTs 2.95 and 3.73). The children also received a booster dose of Menveo, 5 years after a single dose primary vaccination. All subjects in both age groups had hSBA ≥ 1:8 across all serogroups,

					with antibody titers several fold higher than seen after the primary vaccination.
R/0046	Renewal of the marketing authorisation.	23/10/2014	04/12/2014		Based on the review of the available information, the CHMP is of the opinion that the quality, the safety and the efficacy of Menveo continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Menveo continues to be favourable. The CHMP concluded that henceforth the MAH should submit the PSUR on a 3-yearly basis. The CHMP is of the opinion that the renewal be granted with unlimited validity.
II/0048	Deletion of a specification parameter of the finished product. B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	23/10/2014	n/a		Deletion of a specification parameter of the finished product.
PSUV/0045	Periodic Safety Update	09/10/2014	n/a		PRAC Recommendation - maintenance
IB/0047/G	This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	07/08/2014	04/12/2014	Annex II	

II/0042	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC with new information on booster dose from studies V59P13E1 and V59P6E1 previously submitted as FUM 12 and 13. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/06/2014	28/07/2014	SmPC and PL	To ensure optimal antibody levels against all vaccine serogroups , the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W135 and Y. Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations. Studies V59P13E1 and V59P6E1 have indicated persistent immune responses at 5 years post-vaccination as well as upon administration of booster doses (for more information, please refer to section 5.1 of the SmPC).
II/0034	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	24/07/2014	04/12/2014	SmPC and PL	
II/0038	Update of section 4.8 of the SmPC as requested in the outcome of assessment of the latest PSUR - inclusion of anaphylaxis and extensive swelling as adverse reactions. The Package Leaflet is updated accordingly. In addition, minor changes are made in SmPC sections 6.5 and 6.6 and to the PL to clarify product reconstitution instructions. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the	26/06/2014	28/07/2014	SmPC and PL	Hypersensitivity reaction including anaphylaxis and injection site cellulitis/injection site swelling, including extensive swelling of the injected limb, are adverse drug reactions of Menveo. The frequency of these reactions is unknown as they have not been reported in clinical trials but only occasionally in the post-marketing setting.

	assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH				
IB/0044	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	20/05/2014	n/a		
IB/0043	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	20/05/2014	n/a		
II/0040	Update of SmPC section 4.5 with information on co-administration with Hepatitis A and B vaccines. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/04/2014	28/07/2014	SmPC and PL	Results of a phase 3b, randomized, open-label study to evaluate the safety and immunogenicity of combined hepatitis A/B vaccine when administered concomitantly with Menveo in healthy adults were provided. Concomitant administration of hepatitis A/B vaccine with Menveo versus hepatitis A/B vaccine given without Menveo did not demonstrate any negative impact on the immunogenicity of hepatitis A/B vaccine. Similarly, concomitant administration of hepatitis A/B vaccine in this study did not demonstrate any negative impact on the immunogenicity of Menveo. There was also no substantial difference in reporting of adverse events between the different vaccine groups.
IG/0426	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	11/04/2014	n/a		
IB/0039/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.c.3.a.2 - Change in source of an excipient or	11/02/2014	n/a		

	reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product				
II/0035	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	23/01/2014	n/a		
IB/0037	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	09/01/2014	n/a		
IB/0036	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	09/01/2014	n/a		
IA/0033	B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)	25/10/2013	28/02/2014	SmPC, Labelling and PL	
II/0028/G	This was an application for a group of variations. Change in the manufacturing site for the finished product. Change of vial dimensions. Change of shelf life for finished product. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch	25/04/2013	28/02/2014	SmPC	

	release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale				
II/0018	Update of sections 4.2 and 5.1 of the SmPC to reflect available data in children aged 2-23 months. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/04/2013	28/02/2014	SmPC and PL	Please refer to the assessment report: Menveo-H-C-1095-II-18-AR.
II/0030	To include febrile convulsion and tonic convulsion as adverse reactions in SmPC section 4.8, as requested by the CHMP in the outcome of the assessment of a PSUR. The PL has been updated in accordance. In addition, editorial changes have been made in the list of local representatives in the PL and Annex II has been updated to the latest QRD template version. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH	21/02/2013	28/02/2014	SmPC, Annex II and PL	Cumulatively up to the data lock point of the most recent PSUR (14 March 2012), in total there have been 78 solicited reports of convulsive events from clinical trials, in 70 of which the events were assessed by the investigator as not suspected to be related to Menveo. In addition there have been 11 spontaneous reports. Even though possible alternative causes could be identified for almost all cases, a causal relationship with use of Menveo could not be excluded, therefore the CHMP concluded during the assessment of the most recent PSUR that these events should be included in the SmPC as adverse reactions.

IA/0031	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	01/02/2013	n/a		
IAIN/0032/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	28/01/2013	n/a		
IA/0029	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	20/12/2012	n/a		
IAIN/0026/G	This was an application for a group of variations.	22/08/2012	n/a		

	C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
IB/0024	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	11/07/2012	n/a		
II/0020	Update of section 4.8 of the SmPC in order to include myalgia and injection site cellulitis as per request of the CHMP following assessment of PSUR 2. Further to a review of post-marketing safety data and safety data from clinical trials performed by the MAH, section 4.8 is also updated to include arthralgia, hypersensitivity, syncope and vertigo, and to revise the frequency of injection site pruritus. The PL is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the PL. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH	24/05/2012	27/06/2012	SmPC and PL	Further to the assessment of the second periodic safety update report for Menveo, myalgia and injection site cellulitis were included in the product information with the frequency very common and rare respectively. In addition, based on the safety data available from clinical trials, arthralgia was included as a common adverse reaction and the frequency of injection site pruritus was revised to uncommon. Finally, based on review of post-marketing safety data performed by the MAH, hypersensitivity, syncope and vertigo were also included in the product information with the frequency rare.

IB/0025	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	29/05/2012	n/a		
II/0017	Update of sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC of the vial/vial presentations in order to extend the indication to include children aged 2 to 10 years old and consequential update of section 4.4 of the SmPC to include a warning that booster dose should be considered for persons who remain at risk of exposure to Men A. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to revise the product information according to the QRD template. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	15/03/2012	24/04/2012	SmPC, Annex II and PL	Please refer to Assessment Report EMEA/H/C/001095/II/0017
IA/0022	B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction	06/12/2011	n/a		
IB/0021/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	14/11/2011	n/a		

IA/0019/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	18/10/2011	n/a		
II/0015	Update of section 5.1 of the SmPC to correct the results for the per protocol analysis of study V59P13 as per CHMP request. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the	23/06/2011	26/07/2011	SmPC	The MAH reported a transcription error in data from the previously assessed V59P13 and V59P18 studies, which rendered a subset of immunogenicity results invalid. As a result of the same transcription error three assays were repeated. The MAH provided statistical sensitivity analyses to determine the impact of this invalidation upon the conclusions of both studies and updated the pivotal results for V59P13 and V59P18 to account for these data. Based on the analysis performed by the MAH, the CHMP concluded

	MAH				the differences as compared to the original data are small and the main conclusions remain unaffected by these corrections. Section 5.1 of the SmPC has been revised to correct the results for the PP population from study V59P13. 1396 (instead of 1483) subjects between 11 and 18 years old and 902 (instead of 961) subjects between 19 and 55 years who received MenACWY are now included in the per protocol (PP) population of study V59P13. There was no impact on the SmPC in relation to study V59P18.
IA/0016/G	This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	24/06/2011	n/a		

IB/0014	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	22/06/2011	n/a		
IA/0013	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	26/04/2011	26/04/2011	SmPC, Labelling and PL	
II/0011/G	This was an application for a group of variations. To introduce a change in the manufacturing process of the finished product and to add a new presentation. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Type of container - Sterile medicinal products and biological/immunological medicinal products B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product	17/02/2011	18/03/2011	SmPC, Labelling and PL	
II/0008/G	This was an application for a group of variations. Introduction of a new filtration step and re-	17/02/2011	25/02/2011		

	introduction of holding time for the liquid formulated bulk. Tightening of the bioburden limit. B.II.b.3.c - Change in the manufacturing process of the finished product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits				
IA/0012	C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV	04/02/2011	n/a		
II/0007	Revision of the directions for product reconstitution. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	16/12/2010	27/01/2011	SmPC	Change in the directions for product reconstitution in section 6.6 of the SmPC. The MenA lyophilized conjugate component dissolves well, but to ensure and easy withdrawal of the dose, the text is changed from "gently shake" to "vial should be shaken vigorously for a few seconds".
IA/0010	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	15/12/2010	n/a	SmPC and Annex II	
IB/0009	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	06/12/2010	n/a		
N/0006	The Marketing Authorisation Holder added the list of local representatives to the Package Leaflet	29/09/2010	n/a	PL	

	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)				
II/0003	Change in immediate packaging of the finished product. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products	22/07/2010	06/09/2010	SmPC	
II/0002	Changes in the manufacturing process of the active substance. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol	22/07/2010	19/08/2010		
IB/0004	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol	06/07/2010	n/a	SmPC	
IA/0005	C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV	06/07/2010	n/a	Annex II	
IA/0001/G	This was an application for a group of variations.	30/04/2010	n/a	Annex II	

	C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities				